Burosumab (KRN23) from Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co. Ltd. met the primary endpoint of an increase in serum phosphorous levels in a Phase III clinical trial testing the biologic in adults with X-linked hypophosphatemia (XLH), but the limited effect on certain secondary endpoints could reduce the product candidate's use in the rare bone-destroying disease.
Ultragenyx believes that burosumab's effects on three measures that impact XLH patients' quality of life will improve beyond the 24-week...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)